Natus Medical Inc (NASDAQ:BABY) has been given an average rating of “Hold” by the six analysts that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $36.00.
BABY has been the subject of a number of research analyst reports. BidaskClub raised Natus Medical from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 23rd. Zacks Investment Research upgraded Natus Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 26th.
In other Natus Medical news, Director Ken Ludlum sold 12,632 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $31.94, for a total value of $403,466.08. Following the completion of the sale, the director now owns 39,406 shares in the company, valued at $1,258,627.64. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Austin Francis Noll III sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $31.14, for a total value of $622,800.00. Following the completion of the sale, the vice president now owns 105,193 shares of the company’s stock, valued at approximately $3,275,710.02. The disclosure for this sale can be found here. 1.65% of the stock is currently owned by insiders.
The company has a 50-day simple moving average of $29.96 and a 200 day simple moving average of $27.03. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.70 and a quick ratio of 1.18. The firm has a market capitalization of $1.09 billion, a P/E ratio of 22.48 and a beta of 0.57. Natus Medical has a fifty-two week low of $23.53 and a fifty-two week high of $37.90.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.04. The firm had revenue of $125.50 million during the quarter, compared to the consensus estimate of $122.85 million. Natus Medical had a positive return on equity of 10.79% and a negative net margin of 7.38%. The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.35 earnings per share. On average, equities research analysts predict that Natus Medical will post 1.27 EPS for the current fiscal year.
Natus Medical Company Profile
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Featured Article: What impact do institutional investors have on markets?
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.